FDA issues more than 55 warning letters to online GLP-1 sellers
The agency targeted direct-to-consumer advertising by compounded GLP-1 marketers rather than product quality.
FDA issued more than 55 warning letters to online sellers of compounded GLP-1 medicines, citing misleading direct-to-consumer advertising in a range of forms.
The recurring problem was marketing that blurred the line between a compounded preparation and an FDA-approved medicine, or that omitted risk information the approved products must carry.
A warning letter is not a finding of patient harm. It is a public record searchable by company name, and worth checking before enrolling anywhere.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement or the clinical review behind a prescription.
Where a development moves a figure we publish, the change is recorded with its date on our methodology page rather than edited in silently.
How to verify this yourself
Regulatory claims should be checked against the agency rather than coverage of the agency. FDA publishes warning letters searchable by company name and a drug shortage database, both free and both more current than any summary.